Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto produced computer hardware and software designed to enable farmers to increase yield and productivity through more precise planting. In 2013 Monsanto purchased San Francisco-based Climate Corp for $930 million. Climate Corp. makes local weather forecasts for farmers based on data modelling and historical data; if the forecasts were wrong, the farmer was compensated. In 2015 Monsanto tried to acquire Swiss agro-biotechnology rival, Syngenta, for US$46.5 billion, but failed. In 2015 Monsanto was the world's biggest supplier of seeds, controlling 26% of the global seed market (Du Pont was second with 21%). Monsanto is the only manufacturer of white phosphorus for